{"prompt": "['Special situations are not in themselves AEs, but may result in AEs. Each AE associated', 'with a special situation should be recorded separately on the Adverse Event eCRF. If the', 'associated AE fulfils seriousness criteria, the event should be reported to the Sponsor', 'immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).', 'Adverse events associated with special situations should be recorded as described below for', 'each situation:', 'Accidental overdose: Enter the AE term. Check the \"Accidental overdose\" and', '\"Medication error\" boxes.', 'Medication error that does not qualify as an overdose: Enter the AE term. Check the', '\"Medication error\" box.', 'Medication error that qualifies as an overdose: Enter the AE term. Check the', '\"Accidental overdose\" and \"Medication error\" boxes.', 'In addition, all special situations associated with study treatment, regardless of whether they', 'result in an AE, should be recorded on the Adverse Event eCRF and reported to the', 'Sponsor immediately (i.e., no more than 24 hours after learning of the event). Special', 'situations should be recorded as described below:', 'Accidental overdose: Enter the drug name and \"accidental overdose\" as the event term.', 'Check the \"Accidental overdose\" and \"Medication error\" boxes.', 'Medication error that does not qualify as an overdose: Enter the name of the drug', 'administered and a description of the error (e.g., wrong dose administered, wrong dosing', 'schedule, incorrect route of administration, wrong drug, expired drug administered) as', 'the event term. Check the \"Medication error\" box.', 'Medication error that qualifies as an overdose: Enter the drug name and \"accidental', 'overdose\" as the event term. Check the \"Accidental overdose\" and \"Medication error\"', 'boxes. Enter a description of the error in the additional case details.', 'Intercepted medication error: Enter the drug name and \"intercepted medication error\" as', 'the event term. Check the \"Medication error\" box. Enter a description of the error in the', 'additional case details.', 'As an example, an accidental overdose that resulted in a headache would require the', 'completion of two Adverse Event eCRF pages, one to report the accidental overdose and', 'one to report the headache. The \"Accidental overdose\" and \"Medication error\" boxes would', 'need to be checked on both eCRF pages.', '5.5', 'FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS', '5.5.1', 'Investigator Follow-Up', 'The investigator should follow each AE until the event has resolved to baseline grade or', 'better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or', 'the patient withdraws consent. Every effort should be made to follow all SAEs considered to', 'be related to study drug or trial-related procedures until a final outcome can be reported.', 'During the study period, resolution of AEs (with dates) should be documented on the', \"Adverse Event eCRF and in the patient's medical record to facilitate source data verification.\", 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '79 / Protocol MO40628, Version 12']['All pregnancies reported during the study should be followed until pregnancy outcome.', '5.5.2', 'Sponsor Follow-Up', 'For SAEs, AEs of special interest, and pregnancies, the Sponsor or a designee may', 'follow up by telephone, fax, email, and/or a monitoring visit to obtain additional case details', 'and outcome information (e.g., from hospital discharge summaries, consultant reports,', 'autopsy reports) in order to perform an independent medical assessment of the reported', 'case.', '5.6', 'ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE EVENT', 'REPORTING PERIOD', 'After the end of the adverse event reporting period (defined as seven months after the last', 'dose of study treatment), all deaths, regardless of cause, should be reported through use of', 'the Long-Term Survival Follow-Up eCRF.', 'In addition, if the investigator becomes aware of:', 'an SAE that is believed to be related to prior exposure to study drug', 'heart failure, AEs of special interest, or non-breast-related second primary malignancies,', 'regardless of causality', 'the event should be reported through use of the Adverse Event eCRF. However, if the', 'EDC system is not available, the investigator should report these events directly to the', 'Sponsor or its designee, either by faxing or by scanning and emailing the paper Clinical', 'Trial Serious Adverse Event / Adverse Event of Special Interest Reporting Form using', 'the fax number or email address provided to investigators.', '5.7', 'EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS,', 'INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES', 'The Sponsor will promptly evaluate all SAEs and AEs of special interest against cumulative', 'product experience to identify and expeditiously communicate possible new safety findings', 'to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.', 'To determine reporting requirements for single AE cases, the Sponsor will assess the', 'expectedness of these events using the following reference documents:', \"Perjeta Investigator's Brochure (source for Perjeta IV and for pertuzumab and\", 'trastuzumab FDC SC)', \"Herceptin Investigator's Brochure (source for Herceptin IV)\", 'The Sponsor will compare the severity of each event and the cumulative event frequency', 'reported for the study with the severity and frequency reported in the applicable reference', 'document.', \"Reporting requirements will also be based on the investigator's assessment of causality and\", 'seriousness, with allowance for upgrading by the Sponsor as needed.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '80 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}